Anthrax countermeasures: Current status and future needs

Biosecurity and Bioterrorism

Volumn 3, Issue 2, 2005, Pages 102-112

  Borio, Luciana L ^a   Gronvall, Gigi Kwik ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIINFECTIVE AGENT;

ANTHRAX; ARTICLE; BIOLOGICAL WARFARE; DISASTER PLANNING; EMERGENCY HEALTH SERVICE; HUMAN; ORGANIZATION AND MANAGEMENT; UNITED STATES;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BIOTERRORISM; DISASTER PLANNING; EMERGENCY MEDICAL SERVICES; HUMANS; UNITED STATES;

EID: 24644466890     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2005.3.102     Document Type: Article

References (56)

1. Bell T. Anthrax cleanup processing inside Hamilton postal facility. Associated Press October 30, 2003.
2. Coffin B, Sgroi TJ. Anthrax clean-up at state department; post-September 11th measures. Risk Manage 2003;50(12): 40. Available at: http://www.rmmag.com/ MGTemplate. cfm?Section=RMMagazine&NavMenuID=128&template=/ Magazine/DisplayMagazines.cfm&MGPreview=1&Volume=50&IssueID= 205&AID=2210&ShowArticle=1 Accessed May 10, 2005.
3. Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001;2(2):233-247.
4. Gillis J. U.S. to buy anthrax vaccine. Washington Post March 12, 2004;A01.
5. Department of Health and Human Services Press Office. HHS Fact Sheet: Biodefense Preparedness: Record of Accomplishment. Washington, DC: DHHS; 2004.
6. Alibek K, Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World, Told from the Inside by the Man Who Ran It. New York: Random House; 1999.
7. Athamna A, Massalha M, Athamna M, et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother 2004;53(2):247-251.
8. Athamna A, Athamna M, Abu-Rashed N, et al. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 2004;54(2):424-428.
9. Jefferds MD, Laserson K, Fry AM, Roy S, Hayslett J, Grummer-Strawn L, Kettel-Khan L, Schuchat A; Centers for Disease Control and Prevention Anthrax Adherence Team. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis 2002;8(10):1138-1144.
10. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, Factor S, Jones J, Ridzon R, Williams I, Rosenstein N; CDC Adverse Events Working Group. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002;8(10):1124-1132.
11. Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature 2004 Dec 16;432(7019):901-904.
12. Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun 2002;70(11):6231-6241.
13. Centers for Disease Control and Prevention. Emergency Preparedness and Response, Anthrax Q & A: Preventive Therapy. Updated March 25, 2005. Available at: http://www. bt.cdc.gov/agent/anthrax/faq/preventive.asp. Accessed May 10, 2005.
14. Miller J. Wrangling impedes transfer of civilian anthrax vaccine. New York Times August 20, 2004;16.
15. Department of Health and Human Services. HHS Awards BioShield Contract for AVA Anthrax Vaccine. Bethesda, Md: DHHS; May 6, 2005. Available at: http://www.hhs.gov/ news/press/2005pres/20050506.html. Accessed on May 18, 2005.
16. Food and Drug Administration. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Federal Register May 31, 2002;67(105): 37988-37998. Available at: http://frwebgate6.access.gpo. gov/cgi-bin/waisgate. cgi?WAISdocID=741655117794+ 0+0+0&WAISaction=retrieve Accessed May 10, 2005.
17. Hearing Before the House Committee on Government Reform. Project BioShield: Contracting for the Health and Security of the American Public. 108th Cong., 1st Sess (2003). Available at: http://frwebgate.access.gpo.gov/cgibin/ useftp.cgi?IPaddress=162.140.64.128&filename= 87141.pdf&directory=/ disk5/wais/data/108_house_hearings Accessed May 10, 2005.
18. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-185.
19. Food and Drug Administration. From Test Tube to Patient: New Drug Development in the United States. 2nd ed. Rockville, Md: Dept. of Health & Human Services, Food and Drug Administration; 1995. Available at: http://www. fda.gov/fdac/special/newdrug/ndd_toc.html Accessed May 10, 2005.
20. Centers for Disease Control and Prevention. Genital Herpes Fact Sheet. Atlanta, Ga: CDC; 2004. Available at: http://www.cdc.gov/std/Herpes/STDFact- Herpes.htm. Accessed May 10, 2005.
21. Bush G. State of the Union, January 28, 2003. Available at: http://www.whitehouse.gov/news/releases/2003/01/ 20030128-19.html. Accessed May 10, 2005.
22. The White House. President Bush Signs Project Bioshield Act of 2004; Remarks by the President at the Signing of S.15-Project Bioshield Act of 2004. July 21, 2004. Available at: http://www.whitehouse.gov/news/releases/2004/07/ 20040721-2.html Accessed May 10, 2005.
23. The Department of Homeland Security (DHS) Appropriations Act. 2004. Available at: http://thomas.loc.gov/cgi-bin/ bdquery/z?d108:H.R.2555 Accessed May 19, 2005.
24. Department of Health and Human Services Press Office. HHS Buys New Anthrax Vaccine for Stockpile: Purchase Is the First Project BioShield Contract. Washington, DC: November 4, 2004. Available at: http://www.hhs.gov/news/ press/2004pres/20041104a.html. Accessed May 10, 2005.
25. Drexler M. Interview with Philip K. Russell, MD, Acting Director, Office of Research and Development Coordination, Office of the Assistant Secretary for Public Health Emergency Preparedness, U.S. Department of Health and Human Services. Biosecur Bioterror 2004; 2(3):141-145.
26. Department of Health and Human Services. Acquisition of Therapeutic Products for Treatment of Inhalational Anthrax Disease for the Strategic National Stockpile. [RFP] Washington, DC: DHHS; 2004. Available at: http://fsl.eps. gov/EPSData/HHS/Synopses/37271/Reference-Number-2004-N-01385/ AnthraxTherapeuticRFPFinal.pdf. Accessed May 10, 2005.
27. National Institute of Allergy and Infectious Diseases. National Biodefense Effort. Bethesda, Md: NIAID; 2004. Available at: http://www2.niaid. nih.gov/biodefense/about/ nbe.htm. Accessed May 10, 2005.
28. National Institute of Allergy and Infectious Diseases. NIAID High Priority Biodefense Products. Bethesda, Md: NIAID; 2004. Available at: http://www2.niaid.nih.gov/ Biodefense/Research/high_priority.htm. Accessed May 10, 2005.
29. Marczewski RW. Opinion: bridging the virtual valley of death for technology R&D. The Scientist 1997;2(11). Available at: http://www.the- scientist.com/1997/01/20/11/1. Accessed May 10, 2005.
30. Fauci AS. Biodefence on the research agenda. Nature 2003 Feb 20;421(6925):787.
31. Hearing Before the House Select Committee on Homeland Security. BioShield: Countering the Bioterrorist Threat. 108th Cong, 1st Sess (May 15, 2003) (testimony of Anthony Fauci, Director National Institute of Allergy and Infectious Diseases). Available at: http://frwebgate.access. gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.128& filename=96176. wais&directory=/disk5/wais/data/108_ house_hearings. Accessed May 10, 2005.
32. National Institute of Allergy and Infectious Diseases. Announcement: Biodefense Countermeasure Development: Project BioShield. Bethesda, Md: NIAID; 2004. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-AI-04- 044.html. Accessed May 10, 2005.
33. National Institute of Allergy and Infectious Diseases. NIAID's Vaccine and Treatment Evaluation Units. Bethesda, Md: NIAID; 2002. Available at: http://www.niaid.nih.gov/ factsheets/vteu.htm. Accessed May 10, 2005.
34. Takafuji E. NIH biodefense research: progress and priorities. Presented at Federal Biodefense Research FY2005; October 20, 2004; Rockville, Maryland.
35. National Institute of Allergy and Infectious Diseases. Small Business Biodefense Program. Bethesda, Md: NIAID; 2002. Available at: http://grantsl.nih.gov/grants/guide/ pa-files/PAS-02-149.html. Accessed May 10, 2005.
36. National Institutes of Health and Centers for Disease Control and Prevention. Small Business Innovation Research Program. Bethesda, Md: NIH, CDC; 2004. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-04- 055.html. Accessed May 10, 2005.
37. BIO, The Biotechnology Industry Organization. Press release: Changes in the SBIR Program Threaten Biotechnology Company Funding. June 16, 2004. Available at: http:// www.bio.org/tax/sbir/20040616fs.asp Accessed May 19, 2005.
38. Pharmaceutical Research and Manufacturers Association. Press Release: PhRMA's Statement on Senate Passage of S. 15, 'Project Bioshield Act of 2004.' Washington, DC: PhRMA; 2004. Available at: http://www.phrma.org/mediaroom/press/ releases/19.05.2004.994.cfm. Accessed May 10, 2005.
39. Fellows PF, Linscott MK, Ivins BE, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001;19(23-24):3241-3247.
40. Divis DA. Accounting shift threatens vaccine program. UPI June 30, 2004. Available at: http://www.upi.com/ view.cfm?StoryID=20040629-063134-5244r. Accessed May 10, 2005.
41. Pollack A. Sometimes, vaccines can be good for business. New York Times October 29, 2004. Available at: http:// www.nytimes.com/2004/10/29/business/ 29inoculate.html. Accessed May 10, 2005.
42. National Institutes of Health. Press Release: NIAID Awards First $27 Million Using New BioShield Authorities. May 10, 2005. Available at: http://www2.niaid.nih.gov/Newsroom/ Releases/bioshield.htm. Accessed May 19, 2005.
43. Travis J. Interview with Michael Goldblatt, Director, Defense Sciences Office, DARPA. Biosecur Bioterror 2003; 1(3):155-159.
44. Gilfillan L, Smith BT, Inglesby TV, et al. Taking the measure of countermeasures: leaders' views on the nation's capacity to develop biodefense countermeasures. Biosecur Bioterror 2004;2(4):320-327.
45. Davis JH. Project BioShield: interpretation and implementation. Panel discussion: at: Federal Biodefense Research FY 2005; October 21, 2004; Rockville, Maryland.
46. Hearing Before the House Select Committee on Homeland Security. BioShield: Countering the Bioterrorist Threat. 108th Cong, 1st Sess (May 15, 2003) (testimony of William A. Haseltine, chairman and chief executive officer of Human Genome Sciences, Inc.). Available at: http:// frwebgate.access.gpo.gov/ cgi-bin/useftp.cgi?IPaddress= 162.140.64.128&filename=96176. wais&directory=/disk 5/wais/data/108_house_hearings Accessed May 10, 2005.
47. Sternberg S. Drug appears to offer 'immunity' against anthrax toxin. USA Today June 24, 2003. Available at: http:// www.usatoday.com/news/health/2003-06- 24-anthrax-usat_ x.htm. Accessed May 10, 2005.
48. Cook-Deegan RM. Does NIH need a DARPA? Issues Sci Technol 1996(Winter). Available at: http://www.issues. org/issues/13.2/cookde.htm. Accessed May 10, 2005.
49. Smith BT, Inglesby TV, O'Toole T. Biodefense R&D: anticipating future threats, establishing a strategic environment. Biosecur Bioterror 2003;1(3):193-202.
50. Gottron F. Project BioShield. CRS Report RS21507. Washington, DC: Congressional Research Service; 2003. Available at: http://www.au.af.mil/au/awc/ awcgate/crs/ rs21507.pdf. Accessed May 10, 2005.
51. National Institutes of Health. NIAID Announces Contracts to Develop Vaccine Against HSN1 Avian Influenza. Bethesda, Md: NIH; May 27, 2004. Available at: http://www. nih.gov/news/pr/may2004/niaid-27.htm. Accessed May 10, 2005.
52. Mondics C. Drug firms on Senate agenda. Philadelphia Inquirer April 10, 2005.
53. Press Release: Lieberman, Hatch, Brownback Call for Next Step in Bioterrorism Preparedness. April 28, 2005. Available at: http.//lieberman. senate.gov/newsroom/release. cfm?id=237026 Accessed May 19, 2005.
54. Hearing Before the Senate Committee on the Judiciary and the Senate Health, Education, Labor and Pension Committee. BioShield II: Responding to An Ever Changing Threat. 108th Cong. 2nd Sess (October 6, 2004). Available at: http://judiciary.senate.gov/hearing.cfm?id= 1327 Accessed May 19, 2005.
55. United States Congress. House Committee on Armed Services. Extraordinary contractual relief under public law 85-804. 1976, Washington: U.S. G.P.O. 64, [13] p.
56. Testimony of Christine Grant, Vice-President, Public Policy and Government Relations, on Behalf of Aventis Pasteur, in The Senate Committee on the Judiciary and the Senate Health, Education, Labor and Pension Committee "BioShield II: Responding to An Ever-Changing Threat." Washington, DC: 2004.